S6 Ep13: Roychowdhury Relays Impact of Recent Infigratinib Approval in FGFR+ Cholangiocarcinoma
OncLive® On Air - En podcast av OncLive® On Air
Sameek Roychowdhury, MD, PhD, discusses the pivotal phase 2 trial with infigratinib in FGFR-positive cholangiocarcinoma, the safety and efficacy achieved with infigratinib, and the next steps for this agent.
